305 related articles for article (PubMed ID: 23639374)
41. IgG-degrading enzyme of Streptococcus pyogenes (IdeS) prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barré syndrome.
Wang Y; Shi Q; Lv H; Hu M; Wang W; Wang Q; Qiao B; Zhang G; Lv Z; Kjellman C; Järnum S; Winstedt L; Zhang Y; Wen J; Hao Y; Yuki N
Exp Neurol; 2017 May; 291():134-140. PubMed ID: 28214515
[TBL] [Abstract][Full Text] [Related]
42. Anti-pan-neurofascin IgM in COVID-19-related Guillain-Barré syndrome: Evidence for a nodo-paranodopathy.
Tard C; Maurage CA; de Paula AM; Cassim F; Delval A; Kuchcinski G; Davion JB; Defebvre L; Bouchiba M; ; Jourdain M; Boucraut J
Neurophysiol Clin; 2020 Oct; 50(5):397-399. PubMed ID: 33190687
[No Abstract] [Full Text] [Related]
43. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers.
Susuki K; Rasband MN; Tohyama K; Koibuchi K; Okamoto S; Funakoshi K; Hirata K; Baba H; Yuki N
J Neurosci; 2007 Apr; 27(15):3956-67. PubMed ID: 17428969
[TBL] [Abstract][Full Text] [Related]
44. Anti-Ganglioside Antibodies Induce Nodal and Axonal Injury via Fcγ Receptor-Mediated Inflammation.
He L; Zhang G; Liu W; Gao T; Sheikh KA
J Neurosci; 2015 Apr; 35(17):6770-85. PubMed ID: 25926454
[TBL] [Abstract][Full Text] [Related]
45. Detection of anti-ganglioside antibodies in Guillain-Barré syndrome.
Zhu W; Li K; Cui T; Yan Y
Ann Transl Med; 2023 Apr; 11(7):289. PubMed ID: 37090048
[TBL] [Abstract][Full Text] [Related]
46. [Autoantibodies in Guillain-Barré Syndrome].
Uchibori A; Chiba A
Brain Nerve; 2015 Nov; 67(11):1347-57. PubMed ID: 26560950
[TBL] [Abstract][Full Text] [Related]
47. Electrophysiologic and immunopathologic correlates in Guillain-Barré syndrome subtypes.
Uncini A; Yuki N
Expert Rev Neurother; 2009 Jun; 9(6):869-84. PubMed ID: 19496690
[TBL] [Abstract][Full Text] [Related]
48. Paranodal destruction and axo-glial dysjunction in a subtype of CIDP with anticontaction-1 antibodies.
Kuwabara S; Misawa S; Mori M
J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):707. PubMed ID: 25758172
[No Abstract] [Full Text] [Related]
49. Ganglioside mimicry and peripheral nerve disease.
Yuki N
Muscle Nerve; 2007 Jun; 35(6):691-711. PubMed ID: 17373701
[TBL] [Abstract][Full Text] [Related]
50. Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes.
Uncini A; Manzoli C; Notturno F; Capasso M
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1157-63. PubMed ID: 20870864
[TBL] [Abstract][Full Text] [Related]
51. Anti-GD1a antibodies from an acute motor axonal neuropathy patient selectively bind to motor nerve fiber nodes of Ranvier.
De Angelis MV; Di Muzio A; Lupo S; Gambi D; Uncini A; Lugaresi A
J Neuroimmunol; 2001 Dec; 121(1-2):79-82. PubMed ID: 11730943
[TBL] [Abstract][Full Text] [Related]
52. Guillain Barré syndrome and other immune mediated neuropathies: diagnosis and classification.
Eldar AH; Chapman J
Autoimmun Rev; 2014; 13(4-5):525-30. PubMed ID: 24434363
[TBL] [Abstract][Full Text] [Related]
53. Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis.
Lonigro A; Devaux JJ
Brain; 2009 Jan; 132(Pt 1):260-73. PubMed ID: 18953054
[TBL] [Abstract][Full Text] [Related]
54. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies.
Zhang G; Lopez PH; Li CY; Mehta NR; Griffin JW; Schnaar RL; Sheikh KA
Brain; 2004 May; 127(Pt 5):1085-100. PubMed ID: 14985267
[TBL] [Abstract][Full Text] [Related]
55. Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach.
Asthana P; Vong JS; Kumar G; Chang RC; Zhang G; Sheikh KA; Ma CH
Mol Neurobiol; 2016 Sep; 53(7):4981-91. PubMed ID: 26374552
[TBL] [Abstract][Full Text] [Related]
56. Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier.
Devaux JJ
Am J Pathol; 2012 Oct; 181(4):1402-13. PubMed ID: 22885108
[TBL] [Abstract][Full Text] [Related]
57. Immune-Mediated Neuropathies.
Gwathmey KG; Smith AG
Neurol Clin; 2020 Aug; 38(3):711-735. PubMed ID: 32703478
[TBL] [Abstract][Full Text] [Related]
58. Axonal pathology in early stages of Guillain-Barré syndrome.
Berciano J
Neurologia (Engl Ed); 2022; 37(6):466-479. PubMed ID: 35779867
[TBL] [Abstract][Full Text] [Related]
59. Diabetes Mellitus Is a Possible Risk Factor for Nodo-paranodopathy With Antiparanodal Autoantibodies.
Appeltshauser L; Messinger J; Starz K; Heinrich D; Brunder AM; Stengel H; Fiebig B; Ayzenberg I; Birklein F; Dresel C; Dorst J; Dvorak F; Grimm A; Joerk A; Leypoldt F; Mäurer M; Merl P; Michels S; Pitarokoili K; Rosenfeldt M; Sperfeld AD; Weihrauch M; Welte GS; Sommer C; Doppler K
Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35314491
[TBL] [Abstract][Full Text] [Related]
60. Autoimmune nodo-paranodopathies 10 years later: Clinical features, pathophysiology and treatment.
Uncini A
J Peripher Nerv Syst; 2023 Jul; 28 Suppl 3():S23-S35. PubMed ID: 37272673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
